88709-17-5

Basic information

• Product Name: ETHYL 2-ETHOXY-4-METHYLBENZOATE
• Synonyms: ETHYL 2-ETHOXY-4-METHYLBENZOATE;Repaglinide Impurity 18
• CAS NO: 88709-17-5
• Molecular Formula: C₁₂H₁₆O₃
• Molecular Weight: 208.25
• Mol File: 88709-17-5.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: ETHYL 2-ETHOXY-4-METHYLBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-ETHOXY-4-METHYLBENZOATE(88709-17-5)
• EPA Substance Registry System: ETHYL 2-ETHOXY-4-METHYLBENZOATE(88709-17-5)

Safety Data

• Hazardous Substances Data: 88709-17-5(Hazardous Substances Data)

Usage

General Description

Ethyl 2-ethoxy-4-methylbenzoate is a chemical compound with the formula C11H14O3. It is a colorless liquid with a floral and fruity odor, commonly used as a fragrance ingredient in various cosmetic and personal care products. It is also used as a flavoring agent in food products. ETHYL 2-ETHOXY-4-METHYLBENZOATE has low solubility in water but is soluble in most organic solvents. It is primarily synthesized through esterification of 2-ethoxy-4-methylbenzoic acid with ethanol.ETHYL 2-ETHOXY-4-METHYLBENZOATE is not expected to volatilize from dry soil surfaces based upon its vapor pressure. It is expected to biodegrade in soil. If released to water, ETHYL 2-ETHOXY-4-METHYLBENZOATE is expected to adsorb to suspended solids and sediment in the water column, and biodegrade in the water column. Based on a classification scheme, an estimate Koc value of around 380, suggests that ETHYL 2-ETHOXY-4-METHYLBENZOATE is expected to adsorb to suspended solids and sediment in the water column. The ester is expected to undergo hydrolysis in aquatic systems based upon its half-life in excess of two days. Volatilization from water and moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 6.5X10-7 atm-cu m/mole. ETHYL 2-ETHOXY-4-METHYLBENZOATE is not expected to volatilize from dry soil surfaces based upon its vapor pressure. It is expected to biodegrade in soil, biodegrade is the primary disposal in that is acceptable.

Upstream product

• 74-96-4 ethyl bromide 
• 50-85-1 2-hydroxy-p-toluic acid 
• 64-67-5 diethyl sulfate 
• 75-03-6 ethyl iodide 

Downstream Products

• 1283118-15-9 2-ethoxy-4-(2-oxo-5,6-diphenyl-1,2,3,4-tetrahydropyrimidin-4-yl)benzoic acid 
• 1283118-16-0 ethyl 2-ethoxy-4-formylbenzoate 
• 1283118-17-1 ethyl 2-ethoxy-4-(2-oxo-5,6-diphenyl-1,2,3,4-tetrahydropyrimidin-4-yl)benzoate 
• 332347-69-0 ethyl 2-ethoxy-4-ethoxycarbonylmethyl-benzoate 
• 99469-99-5 2-(3-ethoxy-4-(ethoxycarbonyl)phenyl) acetic acid 
• 847357-42-0 ethyl 4-(2-tert-butoxy-2-oxoethyl)-2-ethoxy benzoate 
• 110017-07-7 ethyl 4-bromomethyl-2-ethoxy-benzoate 
• 219922-30-2 ethyl 2-ethoxy-4-<2-<<2-cycloheptyl-1-<2-(1-piperidinyl)phenyl>ethyl>amino>-2-oxoethyl>-benzoate 
• 107362-10-7 ethyl 2-ethoxy-4-<2-<<2-cyclohexyl-1-<2-(1-piperidinyl)phenyl>ethyl>amino>-2-oxoethyl>-benzoate 

Relevant articles and documents

An efficient and cost-effective synthesis of 3-ethoxy-4-ethoxycarbonyl-phenylacetic acid: A key acid synthon of repaglinide

This report describes an efficient and commercially viable synthesis of 3-ethoxy-4-ethoxy-carbonyl-phenylacetic acid (1), a key intermediate for the preparation of repaglinide, an oral hypoglycemic agent, from 2-hydroxy-4-methylbenzoic acid in two steps. Thus, 2-hydroxy-4-methylbenzoic acid was first alkylated with ethyl bromide in a polar aprotic solvent and in the presence of an inorganic base to afford ethyl 2-ethoxy-4-methylbenzoate; deprotonation with lithium diisopropylamide (LDA) and quenching the resulting carbanion with carbon dioxide provided the desired compound with improved yield and excellent purity. This procedure is significantly better than a previously published synthesis which involves five steps and requires use of expensive and hazardous reagents.

GLUCOSE UPTAKE INHIBITORS

this invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUTS3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2;R N is H or Me; R1 is optionally one or more halo or methyl groups;R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH2 OH; R 2c and R 2d (if present) are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and(iv) CH 2 OH;R 3a and R 3b are independently selected from H and Me; R 4a is selected from OH,-NH 2, -C(=O)NH 2, and -CH 2 OH; R 4b is either H or Me; R5 is either H or Me; m is 1 or 2; q is 0 or 1;R 11a, R 11b, R 11c and R 11d are independently selected from H, halo, C1-4 alkyl, C 1-4 fluoroalkyl, C 3-4 cycloalkyl, C 1-4 alkyloxy, NH-C 1-4 alkyl and cyano; R 12a and R 12b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH 2 OH; R 12c and R 12d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH 2 OH;R 12e is H or Me; R 13a and R 13b are independently selected from H and Me; R 14 is either H or Me; R 16a and R 16b are independently selected from H and Me; R 6 is selected from H, OMe, and OEt.